Digestive Distress: “Very high dosages (over 20 grams per day) may lead to GI distress (diarrhea, nausea, stomach cramps),” ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...

Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...

Creatine is a safe and effective supplement with very few side effects, unless taken at higher doses than recommended.

All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting® 2025 of AASLDAdditional preclinical data ...

Ritlecitinib effectively reduces psychosocial burden in severe alopecia areata, beyond hair regrowth benefits. Significant improvements in emotional symptoms and activity limitations were observed ...

Two open-label extension studies show that the FcRn blocker nipocalimab has durable efficacy and sustained symptom control ...

Entered strategic partnership with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of 4D-150 in the APAC region; to ...

Phase 3 Trial Design: The FDA agreed with Adagene’s proposed standard-of-care (SOC) control arm for the Phase 3 clinical trial and confirmed that a muzastotug monotherapy arm was also not required.

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...